While earlier studies have clearly shown the potential of hypericin in treating T2D and AD, results from this study provide evidence that hypericin may exert its effects in AD and T2D treatment by interacting with IAPP and Aβ42 peptide to inhibit their deposition. Here, IAPP is linked to Alzheimer disease.